Diana Ernst, RPh, Author at Endocrinology Advisor - Page 3 of 5

Diana Ernst, RPh

Editorial Director
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

FDA Approves New Contraceptive Patch

The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass index (BMI) <30kg/m2 for whom a combined hormonal contraceptive is appropriate.

Programs to Improve Insulin Affordability Launched in United States

Novo Nordisk announced the launch of several new programs that are intended to improve insulin affordability for US patients. These programs include: My$99Insulin: Patients will be allowed to purchase up to 3 vials or 2 packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins (ie, NovoLog, Novolog Mix 70/30, Levemir, Tresiba, Fiasp, Novolin…

Next post in General Endocrinology